by Madaline Spencer | Dec 11, 2025
The U.S Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adults with relapsed/refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy. MZL is a usually...
by Madaline Spencer | Dec 11, 2025
Carla Nester, MD, Professor of Pediatrics-Nephrology at the University of Iowa, discusses one-year phase 3 data of Empaveli (pegcetacoplan) for treatment of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). C3G and...
by Madaline Spencer | Dec 10, 2025
Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester, discusses interim results from a study testing mezagitamab for the treatment of immunoglobulin A (IgA) nephropathy. IgA nephropathy is a kidney disorder that occurs when IgA...
by Madaline Spencer | Dec 9, 2025
Kim Moran, Head of U.S. Rare Diseases at UCB, discusses the approval of Kygevvi (doxecitine and doxribtimine) for patients with thymidine kinase 2 deficiency (TK2d). TK2d is a rare genetic disease characterized by progressive and severe muscle weakness....
by Madaline Spencer | Dec 8, 2025
Michelle Rheault, MD, Pediatric Nephrologist at the University of Minnesota, discusses data from the DUPLEX study testing sparsentan to treat patients with focal segmental glomerulosclerosis (FSGS). FSGS is a rare kidney disorder characterized by...
